Chart pattern: Double Top (weekly)
▼ Broken down
Broke on Nov 06, 2026 · measured target $16.23 (+1%). Details →
Nov 3, 8:11 AM ET
Sotera Health reported third-quarter 2026 net revenues of $324.9 million, up 4.4% from $311.3 million a year earlier, and net income of $58.4 million, or $0.20 per diluted share, compared with $48.4 million, or $0.17, in the prior-year quarter. The company reaffirmed its full-year 2026 constant currency revenue and Adjusted EBITDA growth outlook, which means shareholders see steady profit growth with no change to expectations.
- Q3 2026 net revenues were $324.9 million, up 4.4% from $311.3 million in Q3 2025.
- Q3 2026 Adjusted EPS was $0.29, up 12% from $0.26 per diluted share a year earlier.
- Full-year 2026 outlook reaffirmed: net revenue growth of 5.25% to 6.75% and Adjusted EBITDA growth of 5.75% to 7.25%, both on a constant currency basis.
- Net leverage ratio was 2.9x as of September 30, 2026, compared with 3.2x at December 31, 2025.
Read the filing on SEC.gov ↗
Aug 14, 7:17 AM ET
Sotera Health director James C. Neary resigned from the board as a Class I director, effective August 13, 2026, after notifying the board on August 11, 2026. The company says the resignation was not due to any disagreement over operations, policies or practices, and the board reduced its size to eleven directors.
- James C. Neary resigned as a Class I director, effective August 13, 2026
- Notice of resignation given to the board on August 11, 2026
- Company states no disagreement with management on operations, policies or practices
- Board size fixed at eleven directors as of the effective date
Read the filing on SEC.gov ↗
Aug 6, 7:19 AM ET
Sotera Health reported second-quarter 2026 net revenues of $321.4 million, up 9.2% from a year earlier, and net income of $54 million, or $0.19 per diluted share, compared with $8 million, or $0.03, in the second quarter of 2025. The company raised its full-year 2026 net revenue and Adjusted EBITDA outlook, which points to higher expected results for shareholders this year.
- Q2 2026 net revenues rose 9.2% to $321.4 million; Adjusted EPS was $0.26, up 30%
- Q2 2026 net income was $54 million, or $0.19 per diluted share, versus $8 million, or $0.03, a year earlier
- Full-year 2026 net revenue outlook raised to $1.236 billion to $1.254 billion; Adjusted EBITDA outlook raised to $634 million to $643 million
Read the filing on SEC.gov ↗
May 20, 4:10 PM ET
Sotera Health Company and its subsidiaries signed Amendment No. 7 to its First Lien Credit Agreement on May 20, 2026, under which refinancing lenders will provide $1.42 billion in repriced term loans to Sotera Health Holdings, LLC. The amendment reduces the interest rate spread by 0.25% across the facility's term loans, which lowers the company's borrowing cost on that debt.
- Repriced term loans total about $1.42 billion, provided by 2026 Refinancing Term Lenders under the amended credit agreement.
- Interest margin is Adjusted Term SOFR plus 2.25%, with a 0.00% floor, and the spread on term loans is reduced by 0.25%.
- Repriced loans amortize at 1.00% per year and mature on May 30, 2031.
- A 1.00% soft call premium applies to certain repricing transactions completed within six months after the amendment's effective date.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.